CareDx, Inc. (NASDAQ:CDNA – Get Free Report) CEO John Walter Hanna, Jr. sold 21,998 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $24.02, for a total transaction of $528,391.96. Following the completion of the transaction, the chief executive officer owned 649,642 shares in the company, valued at $15,604,400.84. This represents a 3.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CareDx Price Performance
CDNA stock traded up $1.11 during mid-day trading on Monday, reaching $24.08. The company had a trading volume of 903,382 shares, compared to its average volume of 717,559. The company has a market capitalization of $1.24 billion, a PE ratio of -150.50 and a beta of 2.49. The firm has a 50 day moving average of $20.81 and a 200 day moving average of $19.62. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $24.13.
CareDx (NASDAQ:CDNA – Get Free Report) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.23. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The firm had revenue of $117.70 million during the quarter, compared to analysts’ expectations of $102.03 million. During the same quarter in the prior year, the company earned $0.09 EPS. The company’s revenue was up 39.3% compared to the same quarter last year. Analysts anticipate that CareDx, Inc. will post 0.22 EPS for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on CDNA
Institutional Trading of CareDx
A number of large investors have recently modified their holdings of CDNA. Quarry LP acquired a new stake in shares of CareDx in the 4th quarter valued at $25,000. FNY Investment Advisers LLC purchased a new stake in shares of CareDx during the 3rd quarter worth $31,000. Meeder Asset Management Inc. purchased a new stake in shares of CareDx during the 4th quarter worth $79,000. Quantbot Technologies LP purchased a new stake in shares of CareDx during the 3rd quarter worth $89,000. Finally, CWM LLC lifted its position in shares of CareDx by 119.1% during the 4th quarter. CWM LLC now owns 7,407 shares of the company’s stock worth $140,000 after purchasing an additional 4,026 shares during the last quarter.
About CareDx
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Featured Articles
- Five stocks we like better than CareDx
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
